MARKET OUTLOOK
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The dominance of the TNF-alpha inhibitors and IL-12/23 Stelara (Janssen) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of Novartis’ Cosentyx has been remarkable in the first two years of its launch, but faces competition from the new IL-17 inhibitors, in particular Eli Lilly’s Taltz. In addition, Celgene’s oral PDE-4 inhibitor Otezla has been approved for over three years in the United States and is gaining steady uptake in early lines of therapy.
QUESTIONS ANSWERED

  • · What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients?
  • · How have non-TNF-alpha inhibitor biologics and Otezla been integrated into the treatment algorithm?
  • · What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • · What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • · What are the product-level compliance and persistency rates among drug-treated patients with psoriasis?

Questions Answered in This Report:

    • What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients? 
    • How have non-TNF-alpha inhibitor biologics and Otezla been integrated into the treatment algorithm? 
    •  What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis? 
    •  What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies? 
    •   What are the product-level compliance and persistency rates among drug-treated patients with psoriasis? 

Scope:

The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The dominance of the TNF-alpha inhibitors and IL-12/23 Stelara (Janssen) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of Novartis’ Cosentyx has been remarkable in the first two years of its launch, but faces competition from the new IL-17 inhibitors, in particular Eli Lilly’s Taltz. In addition, Celgene’s oral PDE-4 inhibitor Otezla has been approved for over three years in the United States and is gaining steady uptake in early lines of therapy.


Related Reports

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

View Details

Psoriasis | Disease Landscape and Forecast | G7 | 2020

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details